The Most Important Facts About Cullinan Oncology

Small-cap Healthcare company Cullinan Oncology has moved -2.5% so far today on a volume of 1,647, compared to its average of 130,077. In contrast, the S&P 500 index moved 1.0%.

Cullinan Oncology trades -68.84% away from its average analyst target price of $34 per share. The 3 analysts following the stock have set target prices ranging from $25 to $50, and on average have given Cullinan Oncology a rating of buy.

Anyone interested in buying CGEM should be aware of the facts below:

  • Cullinan Oncology's current price is -59.1% below its Graham number of $25.93, which implies the stock has a margin of safety

  • Based on its trailing earnings per share of -5.48, Cullinan Oncology has a trailing 12 month Price to Earnings (P/E) ratio of -1.9 while the S&P 500 average is 15.97

  • CGEM has a forward P/E ratio of -5.2 based on its forward 12 month price to earnings (EPS) of $-2.03 per share

  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States.

  • Based in Cambridge, the company has 31 full time employees and a market cap of $462,837,280.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.